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Abstract
Colicin E3 is a cytotoxic ribonuclease that specifically cleaves 16S rRNA at the ribosomal A-site to abolish
protein synthesis in sensitive Escherichia coli cells. We have performed extensive mutagenesis of the
96-residue colicin E3 cytotoxic domain (E3 rRNase), assayed mutant colicins for in vivo cytotoxicity, and
tested the corresponding E3 rRNase domains for their ability to inactivate ribosome function in vitro. From
21 alanine mutants, we identified five positions where mutation resulted in a colicin with no measurable
cytotoxicity (Y52, D55, H58, E62, and Y64) and four positions (R40, R42, E60, and R90) where mutation
caused a significant reduction in cytotoxicity. Mutations that were found to have large in vivo and in vitro
effects were tested for structural integrity through circular dichroism and fluorescence spectroscopy using
purified rRNase domains. Our data indicate that H58 and E62 likely act as the acid–base pair during
catalysis with other residues likely involved in transition state stabilization. Both the Y52 and Y64 mutants
were found to be highly destabilized and this is the likely origin of the loss of their cytotoxicity. The
identification of important active site residues and sequence alignments of known rRNase homologs has
allowed us to identify other proteins containing the putative rRNase active site motif. Proteins that contained
this active site motif included three hemagglutinin-type adhesins and we speculate that these have evolved
to deliver a cytotoxic rRNase into eukaryotic cells during pathogenesis.
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Colicins are plasmid-encoded multidomain protein antibi-
otics that are produced by and are active against Escherichia
coli and closely related bacteria. Production of the toxin is
induced under conditions that cause damage to the bacterial
chromosome and forms part of the bacterial SOS response
(Walker 1996). Accordingly, colicin production is believed
to aid in competition for limited nutrient resources, but has
also been implicated in the maintenance of biodiversity
(Kerr et al. 2002) and in bacterial adaptation (Walker et al.
2004). Most colicins characterized to date possess either a
pore-forming activity that causes depolarization of the cy-
toplasmic membrane or a lethal nuclease activity that spe-
cifically targets rRNA, tRNA, or chromosomal DNA. The
DNase-type colicins (E2, E7, E8, and E9) kill cells through
nonspecific, magnesium-dependent cleavage of chromo-
somal DNA (Pommer et al. 2001; Walker et al. 2002).
These enzymes belong to the HNH family of endonucleases
that includes the caspase-activated DNases, responsible for
the degradation of chromatin in eukaryotic apoptosis
(Walker et al. 2002; Scholz et al. 2003). The RNase-type
colicins D and E5 cleave specific, albeit different, tRNA
species (Ogawa et al. 1999; Tomita et al. 2000), and colicin
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E3 (and by homology colicins E4 and E6 and cloacin DF13)
specifically cleaves at the A-site of the 16S rRNA, between
bases A1493 and G1494. This inactivates the ribosome and
arrests protein synthesis, inducing a cold shock-like tran-
scriptional response prior to cell death (Bowman et al. 1971;
Walker et al. 2004).
Cleavage of 16S rRNA by colicin E3 has been reported to
occur only in the context of the intact 70S ribosome (Boon
1972), although other studies indicate that at high concen-
trations of the toxin, both isolated 30S subunits (Ohno-
Iwashita and Imahori 1977) and even naked 16S rRNA
(Ohno and Imahori 1978) are cleaved, although in the latter
case with a lack of specificity. Colicin E3 is cytotoxic only
against E. coli and closely related bacteria because more
distantly related bacteria lack a suitable receptor and/or
translocation system for uptake of the colicin. However, in
vitro colicin E3 is capable of inactivating ribosomes from
distantly related bacterial species (Sidikaro and Nomura
1973). Further to this, colicin E3 has been shown to inac-
tivate chloroplast ribosomes from Euglena gracilis (Steege
et al. 1982) and has a cytostatic activity against leukemic
cells (Smarda et al. 2001). Like other cytotoxic microbial
ribonucleases, colicin E3 is of potential interest as a novel
chemotherapeutic agent (for review, see Makarov and Ilin-
skya 2003).
The nuclease-type colicins are coexpressed and released
in complex with a specific immunity protein that binds with
high affinity to the cytotoxic domain and abolishes its en-
zymatic activity. The equilibrium dissociation constant (Kd)
for both the colicin E3-Im3 and colicin E9-Im9 complexes
has been measured as 10−14 M in 200 mM salt (Wallis et al.
1995; Walker et al. 2003). However, the affinity of the
complex formed between the isolated rRNase domain and
Im3 is two orders of magnitude weaker (10−12 M) and this
reflects additional weak interactions between Im3 and the
translocation domain of the toxin as revealed by the struc-
ture of the colicin E3-Im3 complex (Soelaiman et al. 2001).
Structures for the E3 rRNase domain Im3 complex and the
full-length colicin E3-Im3 complex have been solved at 2.4
Å and 3.0 Å, respectively (Carr et al. 2000; Soelaiman et al.
2001). The location of the active site of colicin E3 was
originally predicted through the similar structural arrange-
ment of H58 and E62 of E3 rRNase with the catalytic resi-
dues of the nonspecific ribonuclease barnase (Carr et al.
2000). Subsequent mutation of these residues to alanine in
the full-length toxin showed that these mutations did indeed
abolish colicin cytotoxicity in a cell extract containing the
protein (Soelaiman et al. 2001). This study did not, how-
ever, rule out the possibility that these mutants are either
structurally compromised or indeed that mutation abolishes
the ability of the cytotoxic domain to reach its cellular target
in the bacterial cytoplasm. Because little is known about the
mechanism of inner-membrane translocation by E3 rRNase,
the latter is of particular concern.
Here we extend this work to assign unambiguously active
site residues through extensive site-directed mutagenesis
and in vivo cytotoxicity assays by using purified mutant
colicins. Mutant rRNase domains were tested in in vitro
ribosome inactivation assays and their structural integrity
and stability assessed through spectroscopic methods. Our
findings support the idea that the rRNase activity of colicin
E3 is mediated in a similar way to that of barnase and other
members of the T1 ribonuclease family, with H58 and E62
of E3 rRNase acting as the acid–base pair. We identify other
residues, the mutations of which abolish or significantly
reduce cytotoxicity without significant perturbation of the
rRNase structure, giving a fuller picture of the arrangement
of the E3 rRNase active site. In addition, we identified a
further class of mutations that led to a loss of cytotoxicity
through destabilization of the rRNase structure. Defining
the E3 rRNase active site has allowed us to identify a mini-
mal catalytic motif used to identify other E3-like rRNase
domains involved in biological processes such as plant–
microbe interactions.
Results
Identification of Col− mutants
Mutant colicin E3 proteins were purified in complex with
the immunity protein Im3 and tested for cytotoxicity against
colicin-sensitive E. coli cells in an agar plate spot test assay
(Fig. 1). In this assay, serial fivefold dilutions of the toxin
are spotted onto a growing lawn of E. coli cells and cyto-
toxicity indicated by a clear or hazy zone in the cell lawn.
For this in vivo activity assay, the intact colicin E3-Im3
complex was used because it displays a substantially greater
cytotoxic activity than the uncomplexed colicin (Walker et
al. 2003). We initially targeted residues identified by Carr et
al. (2000) as likely involved in catalysis or substrate binding
through a structural similarity of the putative E3 rRNase
active site with the active site of barnase. In total, 21 mutant
colicin complexes were purified and tested for cytotoxicity
by this method.
Spot tests showed that the mutant colicins Y52A, D55A,
H58A, E62A, and Y64A are devoid of cytotoxic activity
and the activity of the R40A, R42A, E60A, and R90A mu-
tants are diminished to <1% of the wild-type protein (Fig.
1). This is consistent with predictions based on structural
alignments and previous mutational studies that implicated
H58 and E62 in the catalytic center of the protein (Carr et al.
2000; Soelaiman et al. 2001). This analysis predicted that
H58 and E62 were analogous to the catalytic residues of
barnase H102 and E73 that act as the general acid and
general base in the transesterification step of RNA hydro-
lysis (Carr et al. 2000). The use of histidine and glutamate
side chains as the catalytic residues for the acid–base hy-
drolysis of RNA is thought to be universal for members of
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the T1 ribonuclease family (Irie 1997) and is in contrast to
the mechanism used by members of the RNase A family,
where these roles are fulfilled by two histidine residues
(Cuchillo et al. 1997). Of the four histidine residues in E3
rRNase, only mutation of H58 was found to be important for
cytotoxicity, with mutation of H7, H10, and H71 having no
significant effect on colicin activity (Fig. 1).
Purification of mutant rRNase domains
The significant reduction or, in some cases, abolition of
colicin activity of nine of the mutations is in agreement with
previous data and predictions based on structural studies
(Carr et al. 2000; Soelaiman et al. 2001), but does not rule
out the possibility that the identified mutations have an ef-
fect on colicin import rather than directly on substrate bind-
ing and catalysis. Destabilization of the rRNase domain
could also be a significant factor in reducing or even abol-
ishing the catalytic activity of the toxin. Destabilizing mu-
tational effects on the toxin may well be masked by the
presence of the immunity protein Im3, which binds strongly
to the rRNase domain, and has been shown to considerably
reduce its susceptibility to proteolysis (Ohno et al. 1977;
Walker et al. 2003). Little is known about how the E3
rRNase domain is able to cross the E. coli inner membrane.
In the case of the colicin E9 DNase domain, it has been
shown that this enzyme is capable of forming channels in
planar lipid bilayers and this is thought to be directly related
to the ability of the enzyme to cross the inner membrane of
susceptible cells (Mosbahi et al. 2002). This may not be the
case for the E3 rRNase, but in the absence of a clear mecha-
nism of inner-membrane translocation, it cannot be ruled
out that a point mutation may impair this function.
Because we were interested in the location of the E3
rRNase active site, it was necessary to exclude both the
possibility that the mutant proteins were impaired in their
ability to enter the cytoplasm or that they were significantly
destabilized in the absence of the immunity protein. In order
to address these points, we assessed the in vitro RNase
activity of mutant rRNase domains and used fluorescence
and CD to probe their structure and stability.
We have reported previously that the purification of the
colicin E3 rRNase domain is readily accomplished using a
tandem expression system in which the cytotoxic domain is
coexpressed with its inhibitor Im3 followed by denatur-
ation/renaturation of the isolated domain (Walker et al.
2003). Difficulty purifying the rRNase R42A and H71A
mutants by this method excluded them from further study
and suggested that these mutations cause structural changes
to the enzyme. In addition, we could only obtain the inactive
E62A mutant in low yield. The other mutant rRNase do-
mains, H7A, H10A, K14A, T31A, G37A, R40A, K47A,
Y52A, D55A, H58A, E60A, Y64A, K84A, K89A, and
R90A, could all be purified in similar or greater quantity
than the wild-type protein. Molecular weights for the mu-
tant rRNase domains obtained by electrospray ionization
mass spectrometry were within 2 Da of those expected,
showing that the mutant rRNase domains were not degraded
in the producing cell or during the purification process (data
not shown).
Correlation between in vitro enzymatic
activity and in vivo cytotoxicity
We tested the ability of purified mutant rRNase domains to
inactivate E. coli ribosomes in vitro through a coupled tran-
Figure 1. In vivo cytotoxicity assays of mutant colicin E3-Im3 complexes.
Cytotoxicity of the purified colicin E3 alanine mutants was assessed by
spotting a fivefold serial dilution of purified colicin E3-Im3 complex from
a starting concentration of 1 mg mL−1 onto a growing lawn of E. coli JM83
cells (see Materials and Methods). Clear zones in the cell lawn indicate cell
killing by colicin E3, and hazy zones indicate partial toxicity.
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scription-translation assay. We were primarily interested in
determining if the mutations that caused a significant or
total loss of cytotoxicity in the full-length colicin had a
corresponding effect on the in vitro activity of the rRNase
domain. In this assay, wild-type E3 rRNase domain was
found to be active down to around nanomolar concentra-
tions (data not shown). We assayed the mutant rRNase do-
mains at a single concentration of 10 nM. Activity was
assessed through the production of a reporter protein, firefly
luciferase, which was quantitated by measuring its enzy-
matic activity through chemiluminescence (see Materials
and Methods). Mutant rRNase domains were considered to
be enzymatically active if the production of firefly lucifer-
ase was <1% of the buffer control. We found an excellent
correlation between cytotoxicity and in vitro enzymatic ac-
tivity, with the rRNase domain mutants R40A, Y52A,
D55A, H58A E60A, E62A, Y64A, and R90A all showing
lowered or absent in vitro enzymatic activity at 10 nM (Fig.
2). In the case of the D55A, H58A, and E62A mutants, we
observed an apparent increase in translational activity. The
reason for this is not known, although we note that the
standard deviations in these cases are relatively large. In
addition, we tested the mutant rRNase domains H7A,
H10A, K14A, T31A, G37A, K47A, K84A, and K89A.
These mutations, which had little effect on colicin cytotox-
icity, had no measurable effect on in vitro rRNase activity
under the conditions of the assay. Because mutations that
had a significant effect on colicin activity had a correspond-
ing effect on the in vitro enzymatic activity of the isolated
rRNase domain, we can conclude that these mutations di-
rectly affect the ability of the colicin to cleave 16S rRNA.
Thus, it can be ruled out that the absent or reduced cyto-
toxicity of the inactive and partially active mutant proteins
is due to a loss of the ability of the rRNase domain to
translocate into the cytoplasm.
Structure and stability of mutant E3 rRNase domains
In order to determine if the structure and stability of mutant
rRNase domains had been significantly perturbed by muta-
tion, we used fluorescence and far-UV CD measurements to
look for changes in secondary and tertiary structure. It
would be expected that any effects would be most readily
observed in the context of the isolated E3 rRNase domain,
because even highly destabilizing mutations in the >500
residue full-length colicin may lead to only minor changes
in fluorescence or CD spectra.
E3 rRNase has a fluorescence emission spectrum charac-
teristic of a folded protein with tryptophan side chains bur-
ied in the protein core, displaying a max of 330 nm (Walker
et al. 2003). Spectra for all mutant rRNase domains were
found to be similar to those of the wild-type protein in all
but two cases. These mutants, Y52A and Y64A, both show
max values of 354 nm and are enzymatically inactive (Fig.
3A). This max value is similar to that of free tryptophan in
solution or thermally denatured E3 rRNase and is indicative
of solvent exposure of the E3 rRNase tryptophan residues,
indicating that the Y52A and Y64A mutants are highly de-
stabilized. For the R40, D55A, H58A, E60, E62A, and
R90A mutants, all of which are partially or completely in-
active, the intrinsic tryptophan fluorescence was not altered
significantly from that of the wild type, indicating a simi-
larity in tertiary structure.
The far-UV CD spectrum of wild-type E3 rRNase do-
main displays maxima and minima at 226 and 195 nm,
respectively (Fig. 3B). Deconvolution of the spectrum by
using the program CDNN (Bohm et al. 1992) predicts a
secondary structure content (helix 7%, -sheet 26%, ran-
dom coil 45%) similar to that observed for E3 rRNase in the
crystal structure of the E3 rRNase-Im3 complex (helix 5%,
-sheet 25%, and random coil 31%). For the mutant rRNase
domains D55A, H58A, and E62A, far-UV CD spectra, in-
distinguishable from the wild-type protein, were obtained,
whereas for those Y52A and Y64A differ significantly from
the wild-type spectrum with the maxima at 226 nm absent
and the minima shifted from 195 nm to 198 nm (Fig. 3B).
Calculated secondary structure predictions for Y52A and
Y64A E3 rRNase domains were consistent with a large
reduction in -sheet structure (data not shown). Thus, con-
sistent with the fluorescence data, CD measurements indi-
cate that the structures of Y52A and Y64A E3 rRNase do-
mains are significantly perturbed. It is probable that the loss
of enzymatic activity in these mutants is primarily due to a
loss of the wild-type protein structure, although this does
not rule out the possibility that these residues may also
interact with the substrate.
Figure 2. In vitro ribosome inactivation by E3 rRNase mutants. Mutant
rRNase domains were assessed for the ability to inactivate ribosomes in
vitro through a coupled transcription-translation assay at an rRNase con-
centration of 10 nM. Ribosome function was monitored through the pro-
duction of a firefly luciferase reporter protein. Data are presented as the
translational activity of the in vitro system after colicin E3 treatment nor-
malized to the no E3 rRNase control. Error bars represent the standard
deviation from two independent experiments (see Materials and Methods).
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Thermal denaturation profiles were used to determine if
loss of E3 rRNase function could correlate with decreased
stability of protein structure. Thermal denaturation of wild-
type E3 rRNase, monitored by the change in CD signal at
227 nm, gave a sigmoidal curve characteristic of a single
cooperative transition from the folded to unfolded state
from which a melting temperature (Tm) of 48°C was ob-
tained (Fig. 3C). A similar value (50°C) was obtained from
monitoring the change in max of the intrinsic tryptophan
fluorescence with increasing temperature, indicating that
fluorescence and CD are monitoring the same cooperative
transition (data not shown). The thermal denaturation pro-
file of the inactive mutant protein H58A was found to be
very similar to the wild-type protein with a Tm of 48°C,
indicating that the protein structure has been affected little
by this mutation (Fig. 3C). In contrast, Y52A and Y64A do
not unfold in a cooperative manner, as indicated by their
linear denaturation profiles. Interestingly, and despite the
fact that both the fluorescence and CD indicate that Y52A
and Y64A are highly destabilized, they retain their ability to
bind the immunity protein Im3 (L. Lancaster and C. Klean-
thous, unpubl.).
Functional organization of the E3 rRNase domain
The data presented here strongly support the hypothesis that
the H58 and E62 constitute the catalytic pair of the enzyme.
These amino acids lie close to the side chains of R40, D55,
E60, and R90, residues that were also found to be important
to the enzymatic function of E3 rRNase but had little effect
on its overall structure (Fig. 4A). From our observations, it
appears that the active center of the protein is located be-
Figure 3. Structural properties of purified mutant E3 rRNase domains probed by intrinsic tryptophan fluorescence and CD. (A) Tryptophan fluorescence
emission spectra of wild-type and mutant rRNase domains. Fluorescence spectra (ex  295 nm) were recorded at a protein concentration of 1 M in 10
mM KPi (pH 7.0) at 25°C. All mutant rRNase domains except Y52A and Y64A displayed emission maxima of 330 (±1) nm, essentially identical to that
of the wild-type protein. Y52A and Y64A rRNase show emission maxima of 354 nm, which is indicative of solvent-exposed tryptophan residues, indicating
that these proteins are destabilized and do not possess a wild-type-like structure under these conditions. (B) Far-UV CD spectra of wild-type and mutant
rRNase domains. (C) Thermal denaturation profiles of wild-type and mutant E3 rRNase domains. Comparison of thermal denaturation profiles for wild-type
E3 rRNase, H58A, and Y52A monitored by the change in the far-UV CD signal at 227 nm.
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tween residues 40 and 90 of the E3 rRNase domain. Clearly,
the active center lies away from the immunity protein bind-
ing site in the tertiary structure of E3 rRNase (Fig. 4A). In
the primary sequence, the immunity protein binding site
constitutes two sets of almost contiguous sequence from
residues 2–15 and 25–41 of E3 rRNase (Carr et al. 2000).
With the exception of R40, mutation of residues within the
N-terminal 41 amino acids (H7, H10, K14, K30, T31, G37,
K39) did not cause a significant decrease in E3 rRNase
function (Fig. 4A). Because all of these mutants were iso-
lated bound to Im3, through the tandem expression strategy,
this further implies that binding to Im3 has not been grossly
destabilized. From our observations, it appears that the E3
rRNase domain can be nominally split into two functional
regions, with residues that contact the immunity protein
located in an N-terminal portion of the protein and an active
site composed mainly or completely of C-terminal residues.
Discussion
In this work we have identified residues of the colicin E3
rRNase domain likely to be involved directly in its highly
specific rRNase activity. The arrangement of these residues
(R40, D55, H58, E60, E62, and R90) in the active center of
the toxin is shown in Figure 4. Our data support the pre-
diction that H58 and E62 act as the acid–base pair during a
putative transphosphorylation reaction (Carr et al. 2000).
Mutation of either to alanine leads to a complete loss of
colicin cytotoxicity but does not perturb the E3 rRNase
structure. Mutation of D55 to alanine also leads to a com-
plete loss of function, indicating this residue also plays a
key role in catalysis. D55 lies within hydrogen bonding
distance of H58 (2.9 Å) and may serve to stabilize its posi-
tive charge during its role as the proton donor in the trans-
phosphorylation reaction. A similar arrangement of residues
occurs in RNase A, where D121 lies in close proximity to
the general acid H119 (Cuchillo et al. 1997). In this case, it
has been proposed that the major effect of D121 is to orient
the proper tautomer of H119 for catalysis (Schultz et al.
1998). It was also predicted by analogy with the barnase
active site that R40, R90, and K84 of E3 rRNase would play
a role in E3 rRNase activity (Carr et al. 2000) and, although
the R40A and R90A mutants were found to have a consid-
erably reduced activity, mutation of K84 to alanine was
found to have no effect on colicin E3 activity (Fig. 1). The
location of R90 and R40 and their substantial effect on
colicin activity suggest that these residues do indeed play a
role in substrate binding/catalysis, perhaps in transition state
stabilization. The proposed structural effect of mutating
Y52 or Y64 to alanine, resulting in an inactive colicin, was
confirmed by mutation of these residues to phenylalanine.
Both the Y52F and Y64F colicin E3 mutants were found to
be active toxins (J. Leigh, L. Lancaster, and C. Kleanthous,
unpubl.). Mapping the degree of sequence conservation
among colicin rRNase domains along with proposed active
site residues onto the surface of the rRNase domain-Im3
complex confirms that the putative active site cleft is highly
conserved (Fig. 4B). As was predicted previously, the im-
munity protein-binding site of E3 rRNase lies away from
the active site and there is no obvious overlap between the
two. An almost identical relationship between the immunity
protein-binding site and catalytic site occurs in the colicin
E9 DNase-Im9 complex (Kleanthous et al. 1999). Klean-
thous and Walker (2001) have suggested that this arrange-
ment, which appears common to structurally unrelated com-
plexes, engenders a selective advantage for the producing
organism through the ability to generate sequence variation
at the interface of the colicin cytotoxic domain and immu-
nity protein. For colicin E3, we mutated some of the resi-
Figure 4. Structure of the E3 rRNase-Im3 complex highlighting the effect
of alanine substitution on colicin E3 cytotoxicity and sequence conserva-
tion among rRNase-like bacteriocins. (A) Residues colored according to the
effect of mutation on colicin E3 cytotoxicity; red indicates no detectable
cytotoxicity, purple indicates severe impairment of cytotoxic activity, and
green indicates little change relative to wild-type colicin E3 (see Fig. 1).
The immunity protein (Im3) is colored orange. (B) Surface representation
with E3 rRNase variable residues colored blue and conserved residues
shown in white. The active site residues D55, H58, and E62 (all conserved)
are colored red, and R40, E60, and R90 are colored purple. The right figure
shows the E3 rRNase domain alone rotated ∼90° to show sequence vari-
ability at the E3 rRNase-Im3 interface. This figure was prepared using the
program Pymol v2.1 (PDB code 1E44; Carr et al. 2000).
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dues that contact the immunity protein (H7, H10, K14, K30,
G37, and K39) and showed that these have little or no effect
on colicin cytotoxicity (Fig. 1). When the variation in se-
quence within the colicin E3 rRNase family is mapped onto
the structure of the domain, it is clear that the immunity
protein-binding site is indeed the most sequence-variable
region and so, like the E9 DNase, a ‘hypervariable exosite’
governs inhibitor binding and specificity (Fig. 4B). Such an
exosite mechanism allows for the evolution of protein in-
hibitors with distinct specificities for enzymes carrying
identical active sites (Kleanthous and Walker 2001).
Despite the probable mechanistic similarities between
members of the T1 ribonuclease family and E3 rRNase, they
share no sequence similarity. Indeed, the rRNase domains
of colicin E3 and related bacteriocins do not, on the basis of
their primary sequence, readily fit into any wider RNase
family thus far described. Sequence alignment of E3 rRNase
with homologous bacteriocin rRNase domains from colicins
E3, E4, and E6; cloacin DF13; Lum1A; and Pflu4757 shows
that, as expected, the region of the primary sequence around
the active site is the most highly conserved region of the
enzyme (Fig. 5). Of the residues of E3 rRNase that were
found to be important for cytotoxicity, R40, R42, D55, E62,
and R90 are completely conserved. However, in one se-
quence (Pfu2957, which is not included in Fig. 5) the pro-
posed catalytic histidine (H58) is substituted for threonine
(Parret and De Mott 2002). We speculate that this may
represent an inactive pseudogene, an idea strengthened by
the observation that, unlike all other identified E3 rRNase-
like genes, Pflu2957 has no recognizable rRNase immunity
protein gene associated with it (Parret and De Mott 2002).
Blast searches identified a further three proteins: CV2871
from Chromobacterium violaceum, Haso120001 from Hae-
mophilus somnus, and HecA from Erwinia chrysanthemi,
all classified as hemagglutinin-like adhesins that also carry
putative rRNase domains with an apparent full complement
of catalytic residues (Fig. 5). In the case of HecA, sequence
similarity is limited to the C-terminal region of E3 rRNase,
although, as discussed earlier, the N-terminal portion of the
protein does not appear to be directly involved in catalysis.
For CV2871 and Haso120001, sequence similarity to E3
rRNase is extensive. The best characterized of these hem-
agglutinins is HecA, which contributes to virulence pheno-
types of the plant pathogen E. chrysanthemi (Rojas et al.
2002). Indeed, hemagglutinin-type adhesins are generally
associated with pathogenicity, although to our knowledge
have not previously been identified as possessing cytotoxic
catalytic activities. It is interesting to note that in all three of
the hemagglutinins, the E3 rRNase-like sequence is located
at the extreme C terminus of the protein, as is the case in the
colicins themselves.
If the hemagglutinins identified here do in fact carry an
active E3-like rRNase domain, what then is the role of this
enzymatic domain in animal or plant pathogenicity? Inter- Fi
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estingly, colicin E3 has previously been shown to be active
against chloroplast ribosomes (Steege et al. 1982), which
more closely resemble the prokaryotic ribosome than cyto-
solic eukaryotic ribosomes, and we speculate that chloro-
plast or mitochondrial ribosomes may be the cellular targets
of these novel E3 rRNase-like domains. Further to this, the
supposition that the rRNase-like domains of the hemagglu-
tinins are not active against host ribosomes is supported by
the absence of endogenous immunity-protein-like genes.
Materials and methods
Plasmid construction and protein purification
Site-directed mutagenesis, ligation, and transformation of compe-
tent E. coli cells were performed using standard molecular biology
procedures. Wild-type and mutant E3 rRNase domains were tan-
demly expressed with Im3 from the plasmid pDW1 and the com-
plex isolated by nickel affinity chromatography through an engi-
neered six-histidine tag located at the C terminus of Im3, as de-
scribed previously (Walker et al. 2003). E3 rRNase was eluted
from the column by denaturation of the complex in 6 M guanidine
hydrochloride, the isolated rRNase refolded by extensive dialysis
into water (5 L), followed by 50 mM KPi (pH 7.0; 5 L). A final gel
filtration step (Superdex-75) in 50 mM KPi (pH 7.0) was used to
remove any remaining contaminants (Walker et al. 2003). Vectors
to express colicin E3-Im3 complex (referred to as wild-type colicin
E3-Im3 complex in this paper) were constructed by excision of the
NcoI-XhoI fragment from pDW1 and ligation into the comple-
mentary sites of the pCS4 vector that carries the nuclease E colicin
translocation and receptor binding domains (Garinot-Schneider et
al. 1996). Wild-type and mutant colicin E3-Im3 complexes were
purified by nickel affinity chromatography in a similar way to the
E3 rRNase domain, except the complex was eluted from the col-
umn with a 5-mM to 500-mM imidazole gradient (100 mL on a
5-mL Ni affinity column). A final gel filtration step (Superdex-75)
in 50 mM KPi (pH 7.0) was used to remove any remaining con-
taminants. Im3 was purified as described previously (Walker et al.
2003).
Cell-killing assays
Cell-killing assays were performed by spotting a fivefold serial
dilution of purified colicin E3-Im3 complex, from a starting con-
centration of 1 mg mL−1, onto a growing lawn of E. coli JM83
cells containing the plasmid pTrc99a that confers ampicillin resis-
tance. Plates were prepared by inoculation of E. coli JM83 cells,
1 : 100, into 0.7% molten agar at 42°C, which was overlaid onto
LB-agar plates containing ampicillin (100 g mL−1). Colicin E3-
Im3 complex (2 L) was then spotted onto the plates, which were
incubated overnight at 37°C.
In vitro activity assays
The activity of the purified E3 rRNase domains directed against E.
coli ribosomes was assessed through a coupled in vitro transcrip-
tion-translation assay by using the E. coli S30 extract system for
circular DNA (Promega). The activity of the mutant E3 rRNase
domains was determined by the presence or absence of a reporter
protein (firefly luciferase) encoded by pBESTluc vector (Pro-
mega). Components of the transcription-translation system were
set up according to the manufacturer’s instructions, and E3 rRNase
to a concentration of 10−8 M was added and the mixture incubated
for 5 min at 37°C prior to the addition of 3 g of the template
DNA and then incubated for a further hour at the same tempera-
ture. The quantity of firefly luciferase produced was determined by
chemiluminescence using the Bright-Glo luciferase assay system
(Promega) and measuring the light produced on a TopCount lu-
minometer. The rRNase domains were considered active at this
concentration if the measured light was <1% of that determined in
buffer control experiments.
Spectroscopy
Fluorescence emission spectra were recorded on a Spex-Fluoro-
Max-3 spectrofluorimeter. Spectra were recorded in 10 mM KPi
(pH 7.0) at a protein concentration of 1 M by using an excitation
wavelength of 295 nm with excitation and emission slit widths set
at 3 nm. CD spectra of E3 rRNase domains were recorded on a
Jasco J-810 spectropolarimeter equipped with a Jasco Peltier tem-
perature controller (PFD-4255). Far-UV CD spectra (190–260 nm)
were recorded in 10 mM KPi (pH 7.0) at protein concentrations of
8.5 M in a 1-mm path length quartz cuvette at 25°C. Spectra
shown are the averaged data from five runs with the spectrum of
the buffer subtracted. For thermal denaturation experiments, spec-
tra were run at a protein concentration of 1.7 M in a 10-mm path
length quartz cuvette with magnetic stirring.
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